This study evaluated providing interim treatment with buprenorphine to patients waiting for opioid abuse treatment. 50 patients were randomized to either receive interim buprenorphine treatment or remain on the waiting list. Those receiving buprenorphine had significantly higher rates of negative urine tests for illicit opioids and lower intravenous drug use and psychiatric issues. Interim buprenorphine with technology support showed promise in reducing risks while patients waited for comprehensive treatment.